Interferon Beta-1A

Revision as of 14:32, 21 August 2014 by Deepika Beereddy (talk | contribs)
Jump to navigation Jump to search

Interferon Beta-1A
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Interferon Beta-1A is an immunologic adjuvant that is FDA approved for the treatment of multiple sclerosis. Common adverse reactions include flu-like symptoms including chills, fever, myalgia, and asthenia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Multiple Sclerosis, Relapsing forms

AVONEX (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon Beta-1A in adult patients.

Non–Guideline-Supported Use

Multiple sclerosis, Clinically Isolated Syndrome

Efficacy has been demonstrated in patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Safety and effectiveness in pediatric patients have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon Beta-1A in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Interferon Beta-1A in pediatric patients.

Contraindications

There is limited information regarding Interferon Beta-1A Contraindications in the drug label.

Warnings

There is limited information regarding Interferon Beta-1A Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Interferon Beta-1A Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Interferon Beta-1A Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Interferon Beta-1A Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Interferon Beta-1A in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Interferon Beta-1A in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Interferon Beta-1A during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Interferon Beta-1A in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Interferon Beta-1A in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Interferon Beta-1A in geriatric settings.

Gender

There is no FDA guidance on the use of Interferon Beta-1A with respect to specific gender populations.

Race

There is no FDA guidance on the use of Interferon Beta-1A with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Interferon Beta-1A in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Interferon Beta-1A in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Interferon Beta-1A in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Interferon Beta-1A in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Interferon Beta-1A Administration in the drug label.

Monitoring

There is limited information regarding Interferon Beta-1A Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Interferon Beta-1A and IV administrations.

Overdosage

There is limited information regarding Interferon Beta-1A overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Interferon Beta-1A Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Interferon Beta-1A Mechanism of Action in the drug label.

Structure

There is limited information regarding Interferon Beta-1A Structure in the drug label.

Pharmacodynamics

There is limited information regarding Interferon Beta-1A Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Interferon Beta-1A Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Interferon Beta-1A Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Interferon Beta-1A Clinical Studies in the drug label.

How Supplied

There is limited information regarding Interferon Beta-1A How Supplied in the drug label.

Storage

There is limited information regarding Interferon Beta-1A Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Interferon Beta-1A |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Interferon Beta-1A |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Interferon Beta-1A Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Interferon Beta-1A interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Interferon Beta-1A Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Interferon Beta-1A Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.